CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone866-290-2157
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$48.24 million
Profitability
Miscellaneous
Employees78
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable
CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions
What is CV Sciences' stock symbol?
CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."
How were CV Sciences' earnings last quarter?
CV Sciences Inc (OTCMKTS:CVSI) released its quarterly earnings results on Tuesday, May, 15th. The company reported $0.01 EPS for the quarter. The firm earned $8.07 million during the quarter. CV Sciences had a negative net margin of 11.99% and a negative return on equity of 21.86%. View CV Sciences' Earnings History.
When is CV Sciences' next earnings date?
What price target have analysts set for CVSI?
4 analysts have issued twelve-month price objectives for CV Sciences' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate CV Sciences' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 743.0% from the stock's current price. View Analyst Price Targets for CV Sciences.
What is the consensus analysts' recommendation for CV Sciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CV Sciences.
Has CV Sciences been receiving favorable news coverage?
News stories about CVSI stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CV Sciences earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for CV Sciences.
Who are some of CV Sciences' key competitors?
Some companies that are related to CV Sciences include Minerva Neurosciences (NERV), Evolus (EOLS), Spectrum Pharmaceuticals (SPPI), CytomX Therapeutics (CTMX), Wave Life Sciences (WVE), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Albireo Pharma (ALBO), AMAG Pharmaceuticals (AMAG), Osmotica Pharmaceuticals (OSMT), MannKind (MNKD), Aduro BioTech (ADRO), Syros Pharmaceuticals (SYRS), Evofem Biosciences (EVFM) and Lexicon Pharmaceuticals (LXRX).
What other stocks do shareholders of CV Sciences own?
Who are CV Sciences' key executives?
CV Sciences' management team includes the folowing people:
- Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 62)
- Mr. Michael J. Mona III, Co-Founder, COO & Director (Age 33)
- Mr. Joerg Grasser, CFO, Chief Accounting Officer & Director
- Dr. Joseph Maroon, MD & Director
- Dr. Douglas MacKay ND, Sr. VP of Scientific & Regulatory Affairs and Director
How do I buy shares of CV Sciences?
Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CV Sciences' stock price today?
One share of CVSI stock can currently be purchased for approximately $0.87.
How big of a company is CV Sciences?
CV Sciences has a market capitalization of $87.02 million and generates $48.24 million in revenue each year. The company earns $10 million in net income (profit) each year or $0.09 on an earnings per share basis. CV Sciences employs 78 workers across the globe.View Additional Information About CV Sciences.
What is CV Sciences' official website?
How can I contact CV Sciences?
CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]
MarketBeat Community Rating for CV Sciences (OTCMKTS CVSI)
MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote "Outperform" if you believe CVSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
